|
English
|
正體中文
|
简体中文
|
2850591
|
|
???header.visitor??? :
44654901
???header.onlineuser??? :
1114
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"anadu o"???jsp.browse.items-by-author.description???
Showing items 1-1 of 1 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2025-01-27 |
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma,
|
Janjigian, YY;Van Laarhoven, HWM;Rha, SY;Kozlov, V;Oh, D;Gravina, A;Rapatoni, L;Shoji, H;Hofheinz, RD;Chen, LT;Ford, H;Chenard-Poirier, M;de Giorgio-Miller, V;Chang, YT;Anadu, O;Lee, J |
Showing items 1-1 of 1 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
